Trade Summary

6 months ago, Shenouda Maged, serving as CFO at Relmada Therapeutics, Inc. (RLMD), purchased 500,000 shares at $2.20 per share, for a total transaction value of $1,100,000.00. Following this transaction, Shenouda Maged now holds 788,335 shares of RLMD.

This purchase represents a 173.00% increase in Shenouda Maged's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Wednesday, November 5, 2025 and publicly disclosed via SEC Form 4 filing on Thursday, November 6, 2025 at 2:30 AM ET, 1 day after the trade was made.

Relmada Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.